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Hematopoietic stem cells (HSCs) are multipo­
tent stem cells that emerge early during embryo­
genesis and maintain hematopoiesis throughout 
the entire lifespan of the organism (Dzierzak 
and Speck, 2008; Medvinsky et al., 2011). Al­
though in various vertebrate species the first 
hematopoietic differentiation occurs in the yolk 
sac (Moore and Metcalf, 1970), a growing body of 
data suggests that the aorta­gonad­mesonephros 
(AGM) region plays a key role in the genera­
tion of definitive HSCs (Dieterlen­Lievre, 1975; 
Medvinsky et al., 1993; Müller et al., 1994; 
Medvinsky and Dzierzak, 1996; de Bruijn et al., 
2002; Zovein et al., 2008; Boisset et al., 2010), 
possibly  through  hematopoietic  transition  of 
endothelial cells of the dorsal aorta, which has 
been most clearly shown in zebrafish (Bertrand 
et al., 2010; Kissa and Herbomel, 2010). The 
mouse AGM region is capable of autonomous 
initiation and expansion of HSCs (Medvinsky 
and Dzierzak, 1996; Cumano et al., 2001; 
Taoudi et al., 2008). The early umbilical cord 
and the placenta are also implicated in HSC 
development (de Bruijn et al., 2000; Gekas et al., 
2005; Ottersbach and Dzierzak, 2005; Robin 
et al., 2009). In the mouse embryo, the first 
definitive HSCs are detected at approximately 
the same time in different tissues (Müller et al., 
1994; de Bruijn et al., 2000; Kumaravelu et al., 
2002;  Gekas  et  al.,  2005;  Ottersbach  and 
Dzierzak, 2005), thus their primary origin re­
mains debatable (Medvinsky et al., 2011).
Qualitative and quantitative assessment of 
HSCs can only be performed functionally using 
in vivo limiting dilution long­term repopula­
tion assays (Szilvassy et al., 1990). Although 
human HSCs have been extensively studied in 
fetal, neonatal, and adult sources by transplant­
ation into immunodeficient mice (Larochelle 
et al., 1996; Conneally et al., 1997; Wang et al., 
1997), at early embryonic stages HSCs were 
assayed only in the liver (Oberlin et al., 2010) 
and the placenta (Robin et al., 2009). To date, 
hematopoiesis in the AGM region and the yolk 
sac has been characterized only by immuno­
histological methods and in vitro assays (Tavian 
et al., 1996, 1999, 2001; Oberlin et al., 2002). 
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Hematopoietic stem cells (HSCs) emerge during embryogenesis and maintain hematopoiesis 
in the adult organism. Little is known about the embryonic development of human HSCs. 
We demonstrate that human HSCs emerge first in the aorta-gonad-mesonephros (AGM) 
region, specifically in the dorsal aorta, and only later appear in the yolk sac, liver, and 
placenta. AGM region cells transplanted into immunodeficient mice provide long-term high 
level multilineage hematopoietic repopulation. Human AGM region HSCs, although present 
in low numbers, exhibit a very high self-renewal potential. A single HSC derived from the 
AGM region generates at least 300 daughter HSCs in primary recipients, which disseminate 
throughout the entire recipient bone marrow and are retransplantable. These findings highlight 
the vast regenerative potential of the earliest human HSCs and set a new standard for in vitro 
generation of HSCs from pluripotent stem cells for the purpose of regenerative medicine.
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AGM region and the yolk sac (3 embryos). Thus, HSCs appear 
in the human AGM region at least 5 d earlier than in the yolk 
sac (Table I).
Out  of  26  transplanted  livers,  none  contained  HSCs; 
however, two provided unilineage T cell engraftment (Table I 
and not depicted). In one case, exclusive T cell engraftment 
was also observed in a recipient of an AGM region (Table I 
and not depicted). In these three cases, human T cell contri­
bution increased during the first 4–6 mo, and then decreased 
on a similar timescale (not depicted). Umbilical cords and 
placentas contained no HSCs at all stages tested (Table I).
Short tandem repeat (STR) analysis (Cotton et al., 2000) 
confirmed that the human cells detected in NSG recipient 
mice repopulated by AGM region, yolk sac, and liver cells 
originated from the donor embryo, with no evidence of 
contamination by maternal cells (Tables S1–S4).
The dorsal aorta is the source of HSC activity  
within the human AGM region
In the mouse embryo, definitive HSCs first appear in the 
dorsal aorta (de Bruijn et al., 2000; Taoudi and Medvinsky, 
2007). We tested whether this is true for the human embryo. 
For these experiments, we used human embryos between CS 
15 and 17. The human AGM region was subdissected into 
the dorsal aorta and the urogenital ridges, as previously 
described for the mouse AGM region (de Bruijn et al., 2000; 
Taoudi  and  Medvinsky,  2007).  Cell  suspensions  prepared 
from these tissues were transplanted into irradiated NSG 
recipient mice. In 10 independent experiments performed, 
HSCs were detected in six dorsal aortas, but never in the 
urogenital ridges (see Materials and methods).
High-level hematopoietic repopulation by early  
embryonic HSCs
In NSG mice engrafted with human HSCs from the AGM 
region and the yolk sac, donor CD45+ hematopoietic cells 
first became detectable in the peripheral blood of recipients 
1.5–3 mo after transplantation, with donor cell levels reaching 
It is thought that HSCs mature in intraaortic cell clusters 
budding from the ventral wall of the dorsal aorta (Tavian et al., 
1996, 1999; Jaffredo et al., 1998; Taoudi et al., 2008; Yokomizo 
and Dzierzak, 2010). The maturation of HSCs also occurs in 
deeper layers of the dorsal aorta (Rybtsov et al., 2011).
In this study, we describe spatiotemporal distribution of 
HSCs in the early human embryo and provide evidence that 
the AGM region is the first generator of highly potent HSCs 
in the human. Upon transplantation into immunodeficient 
mice, HSCs derived from the AGM region extensively prop­
agate, migrate to different bones throughout the recipient, 
and provide progressively increasing long­term multilineage 
hematopoietic repopulation of the host animal with robust 
potential for retransplantation. Our study reveals that the first 
human HSCs possess an unprecedented self­renewal capacity. 
A better understanding of embryonic development of human 
HSCs may be instrumental for creating clinically relevant 
protocols for the production of HSCs from human embry­
onic and induced pluripotent stem cells (Kaufman, 2009).
RESULTS
Spatiotemporal distribution of HSCs in the early  
human embryo
AGM regions, yolk sacs, livers, umbilical cords, and placentas 
were obtained from human embryos between Carnegie stages 
(CSs) 12 and 17 (O’Rahilly and Müller, 1987). Cell suspen­
sions prepared from these tissues were transplanted into irra­
diated NOD.Cg­Prkdcscid Il2rgtm1Wjl/Sz (NSG) mice (Shultz 
et al., 2005) within 3–4 h of termination of pregnancy. Cells 
from each individual tissue were split equally between two to 
four NSG recipient mice. In 27 independent experiments, 
HSCs were detected in 10 AGM regions and 3 yolk sacs by 
their capacity to provide human long­term (4–8 mo) multi­
lineage hematopoietic repopulation and by their retransplant­
ability into secondary recipients (Table I). In CS 14 and 15 
human embryos, HSCs were detected exclusively in the AGM 
region (5 embryos). At CS 16 and 17, HSCs were found 
either solely in the AGM region (2 embryos) or both in the 
Table I.  The first HSCs in the human embryo emerge in the AGM region
Carnegie stage (days) Embryonic tissues transplanted
AGM region Yolk sac Liver Umbilical cord Placentas
12 (26) 0/2 0/2 0/2 NA 1c/2
13 (28) 0/2 NA 0/1 NA 1c/2
14 (32) 1a/7 0/7 0/7 0/4 2c/7
15 (33) 4a/5 0/3 0/5 0/4 1c/2
16 (37) 2a + 1b/6 1a/4 0/6 0/6 1c/3
17 (41) 3a/5 2a/4 2b/5 0/3 1c/3
Total 10a + 1b/27 3a/20 2b/26 0/17 7c/19
Cell suspensions prepared from AGM regions, yolk sacs, livers, umbilical cords, and placenta obtained from CS 12–17 human embryos were individually transplanted into 
irradiated NSG mice. Data shown are the number of tissues that gave human hematopoietic repopulation compared to the total number of tissues transplanted. The numbers 
in parentheses indicate an approximate postovulatory gestational age in days accepted for each CS (O’Rahilly and Müller, 1987). NA, not assessed.
aLong-term embryonic multilineage repopulation.
bLong-term embryonic unilineage T cell repopulation.
cTransient maternal unilineage T cell repopulation.JEM Vol. 208, No. 12 
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repopulation in the peripheral blood 
by month 8 after transplantation (Notta 
et al., 2011).
Multilineage differentiation potential of early  
embryonic HSCs
Human multilineage hematopoietic engraftment with AGM 
region and yolk sac cells was biased toward lymphopoiesis, 
dominated by B cells (CD19+; Table III). Approximately one­
third of human B cells in the recipient BM passed the pre–B 
cell stage, as indicated by the IgM expression on the cell surface. 
In the spleen, the proportion of human CD19+IgM+ cells 
was twice as high as in the BM, and in the peripheral blood 
almost all human B cells were IgM+, replicating normal B cell 
development (Fig. 2 A). Human T cells (CD3+) were also 
represented. Double­positive CD4+CD8+ cells prevailed in 
the thymus, and the peripheral blood contained mainly 
single­positive CD4+CD8 and CD8+CD4 T cells, which 
is indicative of normal intrathymic maturation of human T cells 
(Fig. 2 B and Table III). Almost all human T cells in the pe­
ripheral blood of recipient animals expressed  TCRs, as is 
observed in human peripheral blood. Only 1% of T cells 
0.2% on average (range, 0.06–0.54%; n = 13) of total blood 
leukocytes. In all except one case, the percentage of human 
leukocytes in the peripheral blood progressively increased 
and reached up to 90% of total blood leukocytes by 8 mo 
after transplantation (Fig. 1 and Table II).  By the end of the 
observation period (4–8 mo), on average 40% (range, 7–90%; 
n = 10) of leukocytes in the recipient peripheral blood 
were of human origin (Fig. 1 and Table II). In the BM, the per­
centage of human CD45+ cells was higher than in peripheral 
blood, reaching on average 70% (range, 42–94%; n = 7) 
of total BM leukocytes (Table II). Previous studies have 
shown that transplantation of many human umbilical cord 
blood  (UCB)  or  adult  BM  HSCs  into  immunodeficient 
mice results in blood chimerism that is <50% at 10 wk and 
frequently decreases after several months (Cashman et al., 
1997; Ishikawa et al., 2005; Liu et al., 2010). However, 
recent experiments have shown that 10–20 UCB HSCs per 
one NSG recipient mouse are able to provide up to 40%   
Figure 1.  Human AGM region-derived 
HSCs provide progressive growth of hemato-
poietic contribution in NSG mice.  
(A) Representative flow cytometry plots show 
hematopoietic cells in the peripheral blood 
and BM of an NSG mouse transplanted with 
0.33 e.e. of AGM region cells. In this case, the 
AGM region was obtained from a CS 16 embryo. 
The repopulation kinetics was monitored for  
8 mo. hCD45, human CD45. (B) Human  
hematopoietic engraftment kinetics in the 
peripheral blood of 10 NSG recipient mice 
transplanted with human AGM region or yolk 
sac cells. The numbers at the end of the time 
series correspond to the recipient identifica-
tion numbers in Table II.
Table II.  High level hematopoietic repopulation by a single early embryonic HSC
Recipient no. Tissues 
transplanted
Time after 
transplantation
Human CD45+ cells  
in the recipient blood
Human CD45+ cells  
in the recipient BM
Human CD45+ cells  
in the recipient spleen
mo % % %
1 AGM region 4 29 42 4
2 AGM region 4 9 NA NA
3 AGM region 4 24 45 31
4 AGM region 7 39 86 87
5 AGM region 7 73 93 93
6 AGM region 7 22 71 75
7 AGM region 8 90 94 96
8 Yolk sac 4.5 7 NA NA
9 Yolk sac 7.5 56 NA NA
10 Yolk sac 7.5 34 79 87
NSG mice transplanted with HSCs derived from the human AGM region or yolk sac were observed for 4–8 mo. At the end of each experiment, the percentage of human CD45+ 
cells in the recipient peripheral blood, BM, and spleen was assessed by flow cytometry. NA, not assessed as the recipients died.2420 Highly potent human HSCs | Ivanovs et al.
counterparts of mouse lymphopoiesis­biased  and  subtypes 
of long­term repopulating hematopoietic cells, which show 
no capacity for retransplantion (Dykstra et al., 2007).
Extensive amplification of early embryonic HSCs  
in primary recipients
Because one HSC can efficiently restore hematopoiesis in 
vivo (Osawa et al., 1996; Notta et al., 2011), the frequency 
of HSCs can be estimated using a limiting dilution assay 
(Szilvassy et al., 1990). In 9 out of 10 experiments transplant­
ing human AGM region cells into two to four NSG mice, 
one recipient per experiment was found engrafted with human 
hematopoietic cells. Both recipients were repopulated in only 
one experiment (not depicted). To estimate HSC numbers, 
we used software for small numbers of replicates and nonlin­
ear situations (Hu and Smyth, 2009). Our data fit the single­
hit Poisson model (2 = 0.108; P = 0.742), demonstrating 
consistency between all 10 experiments performed with the 
AGM  regions  containing  HSCs.  The  model  calculations 
showed that one human AGM region contains 1.9 HSCs 
(95% CI, 1.0–3.3; Fig. 4 A). If all 23 CS 14–17 AGM regions 
are  considered  (including  nonrepopulating  ones),  the  fre­
quency of HSCs is 0.8 per one human AGM region, which 
is close to the number of definitive HSCs in the mouse AGM 
region (Kumaravelu et al., 2002).
Statistically, human hematopoietic repopulation in each 
engrafted NSG mouse must have arisen mainly from one human 
HSC. The progressive growth in levels of repopulation with 
human hematopoietic cells (Fig. 1) may either be the result of 
gradual enhancement of productivity of this one HSC or, 
alternatively, the result of amplification of HSC numbers in 
recipients. To address this issue, the BM of engrafted primary 
recipients was harvested 4–8 mo after transplantation in five 
independent experiments. BM from an individual recipient 
was transferred into 6–15 secondary recipients. In these ex­
periments, 41 out of 44 secondary recipients transplanted were 
found engrafted with human HSCs. Because each primary 
expressed  TCRs (Fig. 2 C). Additionally, human AGM 
region– and yolk sac–derived HSCs produced CD94+CD3 
NK cells and CD94+CD3+ NKT cells at low frequencies 
(Fig. 2 D and Table III).
The percentage of human CD33+ myeloid cells in the re­
cipient peripheral blood and spleen was 20–25 times lower 
than that of human lymphoid cells; however, the recipient BM 
contained on average 30% (range, 13–70; n = 7) human granu­
locytes  (CD33+CD66b+)  and  monocytes  (CD33+CD14+; 
Fig. 2 E and Table III). Megakaryocytic lineage was also 
readily detectable by appearance of human FSC­HlowCD41a+ 
platelets in the recipient peripheral blood (Fig. 2 F). The re­
cipient BM contained 8% human erythroid cells (CD235a+), 
of which one third coexpressed CD45, indicating their 
immature state (Fig. 2 G).
Additionally, the BM of engrafted recipients plated into 
methylcellulose medium supplemented with human cytokines 
gave rise to human erythroid colonies (burst­forming units­
erythroid [BFU­E]; Fig. 2 H and Table IV), myeloid colonies 
(colony­forming  units­myeloid  [CFU­Myeloid];  Table  IV), 
and mixed erythromyeloid colonies (CFU­Mix; Fig. 2 I and 
Table IV). The human origin of hematopoietic colonies was 
confirmed by flow cytometry analysis (not depicted).
Early embryonic HSCs can be efficiently retransplanted
We tested whether HSCs derived from the human AGM 
region and yolk sac can be serially transplanted. In all eight 
experiments with the AGM region and two experiments with 
the yolk sac, transplantation of BM from primary recipients 
into secondary recipients resulted in sustainable human long­
term multilineage hematopoietic engraftment (Fig. 3). In con­
trast, secondary BM transplantations from all three recipients 
exhibiting long­term unilineage T cell repopulation were 
unsuccessful. This indicates that HSCs colonize the human 
embryonic liver after CS 17. T cell–restricted repopulation 
may originate either from previously undescribed long­term 
persisting embryonic T cell progenitors or from human 
Table III.  Multilineage hematopoietic engraftment in primary recipient mice
Recipient 
no.
Blood BM Spleen Thymus
B T NK Myeloid B T NK Myeloid B T NK Myeloid CD4CD8 CD4+CD8+ CD4+CD8 CD8+CD4
% in gated human CD45+ cells
1 44 39 NA 11 48 19 NA 30 78 12 NA 9 NA NA NA NA
2 67 23 3 4 NA NA NA NA NA NA NA NA NA NA NA NA
3 19 65 5 11 16 42 1 38 29 56 1 15 1 68 25 6
4 77 5 4 12 51 0.1 0.2 45 87 1 1 9 2 84 10 4
5 75 19 2 4 62 1 0.3 37 90 7 0.7 2 3 80 13 4
6 56 25 9 9 61 19 1 20 82 4 3 14 2 85 9 4
7 17 36 31 18 20 4 1.5 74 41 39 11 11 NA NA NA NA
8 59 22 NA 15 NA NA NA NA NA NA NA NA NA NA NA NA
9 63 19 NA 14 NA NA NA NA NA NA NA NA NA NA NA NA
10 26 60 9 6 42 12 2 43 46 41 7 7 2 69 22 7
Data shown are the percentage of B (CD19+), T (CD3+ or CD4+CD8+, CD4+CD8, and CD8+CD4), NK (CD94+CD3), and myeloid cells (CD33+ or CD13+) in the human CD45+ 
cell population in the peripheral blood, BM, spleen, and thymus of NSG mice transplanted with AGM region and yolk sac cells. The recipient identification numbers are the 
same as in Table II. NA, not assessed.JEM Vol. 208, No. 12 
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primary recipients (Fig. 5 A, mice a and b) from five inde­
pendent experiments in which at least one recipient was 
engrafted with AGM region cells (Fig. 5 A, mouse c). The 
entire BM from two coxal bones, two femurs, and two tibiae 
was collected from these nonrepopulated primary recipients 
and transferred into secondary recipients. None of secondary 
recipients showed human hematopoietic engraftment, con­
firming that the AGM region contained only one or two HSCs. 
Secondary transplantations of BM from nonengrafted recipi­
ents transplanted with yolk sac, liver, umbilical cord, and 
placental cells were also unsuccessful (two to five indepen­
dent experiments were performed for each tissue).
To estimate the number of daughter HSCs generated in 
primary recipients by a single HSC derived from the AGM 
region, we performed two independent secondary transplan­
tation experiments using the limiting dilution assay. The BM 
from successfully engrafted primary recipients was harvested 
from the sternum, humeri, ulnae, radii, coxal bones, femurs, 
and tibiae, and then pooled and transplanted in serial dilu­
tions into secondary recipients. In experiment 1, the lowest 
dose transplanted per secondary recipient was 1/75 of total 
BM from primary recipient. All secondary recipients showed 
human long­term multilineage hematopoietic engraftment. 
In experiment 2, the transplanted dose was decreased further 
to 1/300 of total BM per recipient. Again, all secondary 
recipients showed human long­term multilineage hemato­
poietic repopulation (Fig. 4 B). However, in NSG mice 
transplanted with the lowest BM dose the level of human 
contribution, as determined in the peripheral blood 2 mo 
after transplantation, was <3%. Although we did not reach 
the limiting dose, we were close to the extinction of HSC 
activity. Human HSCs were also detected in spleens of primary 
recipients (Fig. 4 C). Thus, one HSC from the human AGM 
region is capable of generating at least 300 daughter HSCs 
upon transplantation. Previous studies have demonstrated a 
recipient was engrafted with approximately one human HSC, 
these results suggest that human HSCs propagated in pri­
mary recipients.
We considered an alternative possibility that the human 
AGM region contained some HSCs that remained dormant 
in primary recipients but could be activated upon secondary 
transplantations.  To  test  this,  we  selected  nonrepopulated 
Figure 2.  Human AGM region–derived HSCs provide long-term 
multilineage hematopoietic engraftment. Representative flow cytom-
etry plots show human B cells (A), T cells (B and C), NK and NKT cells (D), 
granulocytes and monocytes (E), platelets (F), and erythroid cells (G) in the 
peripheral blood, BM, spleen, and/or thymus of an NSG mouse 7 mo after 
it was transplanted with 0.5 e.e. of AGM region cells. In this case, the 
AGM region was obtained from a CS 17 embryo. Note that the staining 
for CD4 and CD8 is shown in gated human CD45+ cells, and for TCRs in 
gated human CD3+ cells. Plating BM of the same recipient into methyl-
cellulose medium supplemented with human cytokines resulted in the 
formation of human erythroid colonies (BFU-Es; H) and mixed erythromy-
eloid colonies (CFU-Mix; I). Bars, 0.5 mm.
Table IV.  Human CFU-C frequency in the BM of primary 
recipient mice
Recipient no. Human CFU-C no. per 10,000 input BM nucleated cells
BFU-E CFU-Myeloid CFU-Mix
1 2.3 ± 0.6 13.0 ± 3.8 2.5 ± 0.4
2 NA NA NA
3 8.7 ± 1.5 34.7 ± 11.2 1.7 ± 0.6
4 7.6 ± 1.4 26.1 ± 4.0 1.7 ± 0.2
5 5.0 ± 1.4 31.0 ± 1.4 0.5 ± 0.7
6 6.3 ± 0.1 16.3 ± 0.4 1.6 ± 0.3
7 6.5 ± 0.7 33.0 ± 4.2 1.5 ± 0.7
8 NA NA NA
9 NA NA NA
10 5.6 ± 0.6 15.4 ± 2.0 1.8 ± 0.3
Data shown are the number ± SD of human CFU-Cs per 10,000 input BM nucleated 
cells. The BM was obtained from NSG mice transplanted with AGM region and yolk 
sac cells. The recipient identification numbers are the same as in Table II. NA, not 
assessed, as the recipients died.2422 Highly potent human HSCs | Ivanovs et al.
present in one human AGM region. However, robust am­
plification of early embryonic HSCs in primary recipients 
allowed us to determine the immunophenotype of daughter 
HSCs. The BM harvested from the sternum, humeri, ulnae, 
very limited self­renewal capacity by HSCs from the human 
UCB and adult BM (Guenechea et al., 2001; McKenzie et 
al., 2006; Liu et al., 2010). Although the microenvironment 
in immunodeficient mice is not optimal for the homeostatic 
expansion of human HSCs (Manz, 2007), human AGM re­
gion–derived HSCs extensively self­renew and amplify in 
these suboptimal conditions, suggesting that their expansion 
potential in physiological conditions is likely to be higher.
Extensive dissemination of daughter HSCs  
in primary recipients
The engraftment of one or two HSCs from the early human 
embryo  results  in  considerable  amplification  of  the  HSC 
pool. We then tested if daughter HSCs stay at one site where 
the lodging of the parental HSC had occurred or if they mi­
grate and disseminate throughout the recipient BM. We used 
two primary recipients repopulated with different AGM 
regions. We harvested BM from each recipient from the fol­
lowing six bones: two coxal bones, two femurs, and two tibiae 
(Fig. 5 A, mouse c). BM cell suspensions from each bone were 
transplanted  separately  into  secondary  recipients  (Fig.  5  A, 
mice 1–6). In experiment 1, all secondary recipients showed 
human  long­term  multilineage  hematopoietic  engraftment 
(Fig. 5 B). Consistent with this, in experiment 2, all secondary 
recipients except one were repopulated with human hemato­
poietic cells. Thus, daughter HSCs generated by one or two 
human  AGM  region­derived  HSCs  disseminate  broadly 
throughout the entire recipient BM.
Daughter HSCs are of the canonical phenotype
Using conventional FACS, it is not technically feasible to 
determine  the  immunophenotype  of  one  or  two  HSCs 
Figure 4.  Extensive amplification of human AGM region–derived 
HSCs in primary recipients. (A) Results of 10 independent experiments 
in which HSCs were detected in AGM regions are plotted as the natural 
logarithm of the fraction of nonengrafted mice versus the dose of donor 
tissues (e.e. per recipient) transplanted in each experiment. The solid line 
shows the mean value. The dotted lines indicate 95% confidence interval. 
The data value with zero negative response (two out of two recipients 
were found engrafted with human HSCs) is represented by a down-pointing 
triangle. (B and C) 8 mo after transplantation, BM (B) and spleen (C) from 
a primary recipient repopulated with a single HSC from the AGM region 
of a CS 16 embryo were harvested and transplanted into secondary  
recipients (two independent experiments). Peripheral blood of secondary 
recipients was analyzed for human CD45+ cell contribution 2 mo after 
transplantation. The ratios below the charts indicate the fraction of total 
BM or spleen transplanted per recipient.
Figure 3.  Human AGM region-derived HSCs provide long-term 
multilineage hematopoietic engraftment upon retransplantation 
into secondary recipients. Representative flow cytometry plots show 
human B (CD19+), T (CD3+), and myeloid cells (CD33+) in the peripheral 
blood (A) and BM (B) of an NSG mouse transplanted with BM from a pri-
mary recipient engrafted with HSCs from a CS 15 AGM region. Secondary 
transplantation was performed 7 mo after primary transplantation. The 
analysis of secondary recipients was performed 7 mo later. Eight indepen-
dent secondary transplantation experiments were performed.JEM Vol. 208, No. 12 
Article
2423
T cell repopulation of maternal origin (Table I, Table S5, and 
not depicted). The placenta contains maternal blood, and 
T cells from human blood can readily expand in immuno­
deficient mice (van Rijn et al., 2003). An older 15­wk­old 
placenta readily provided long­term multilineage hematopoi­
etic repopulation of fetal origin in all three recipients (each 
received 1/30 of total placental cells; Table S6 and not de­
picted). Thus, in contrast to the early CS 12–17 placenta, 
the midgestation human placenta does possess HSC activity.   
In the mouse embryo, definitive HSCs appear in the pla­
centa concomitantly with the AGM region (Gekas et al., 
2005; Ottersbach and Dzierzak, 2005).
DISCUSSION
Although  the  embryonic  development  of  HSCs  has  been 
studied in various vertebrate species (Medvinsky et al., 2011), 
the generation of the first HSCs during human embryogene­
sis  remains  a  largely  unexplored  topic.  The 
present concept of the embryonic development 
of the human hematopoietic system is primarily 
based  on  morphological  and  in  vitro  studies 
(Tavian et al., 1996, 1999, 2001; Oberlin et al., 
2002). By using functional in vivo long­term 
repopulation assays, we conducted systematic 
analysis  of  the  spatiotemporal  distribution  of 
HSCs in the early human embryo. We have 
shown that the AGM region, more specifi­
cally the dorsal aorta, is the first generator of 
HSCs in the human. Interestingly, although in 
the  mouse  embryo  definitive  HSCs  appear 
concomitantly in the AGM region, yolk sac, 
umbilical  cord,  and  placenta  (Müller  et  al., 
1994; de Bruijn et al., 2000; Kumaravelu et al., 
2002;  Gekas  et  al.,  2005;  Ottersbach  and 
Dzierzak, 2005), in the human embryo, the tim­
ing of HSC appearance in these sites is clearly   
radii, coxal bones, femurs, and tibiae of primary recipients 
engrafted with a single HSC from the human AGM region 
was sorted into four cell populations based on expression of 
human CD34 and CD38 antigens, and then transplanted 
into secondary recipients (Fig. 6 A). In two independent 
experiments, human HSCs were found exclusively within 
CD34+CD38/lo cell fraction (Fig. 6 B). Thus, HSCs derived 
from the early human embryo generate numerous HSCs 
of the canonical phenotype (Bhatia et al., 1997; McKenzie 
et al., 2006).
The human placenta develops HSCs later  
than the AGM region
In 19 independent experiments, we transplanted irradiated 
NSG mice with CS 12–17 placental cells and observed no 
long­term  multilineage  engraftment  upon  transplantation. 
Instead, in seven cases, placenta provided transient unilineage 
Figure 5.  Extensive recipient BM colonization  
by daughter HSCs generated from a single AGM 
region-derived HSC. (A) AGM region cells obtained 
from a CS 15 embryo were transplanted into three NSG 
mice (0.33 e.e. per recipient). Only one of the three re-
cipients showed human hematopoietic repopulation 
(mouse c). We confirmed by secondary transplantation 
that the other two recipients (mice a and b) contained no 
activatable HSCs. To test if the single human HSC that 
repopulated mouse c had generated daughter HSCs 
which could spread across the recipient BM, BM cells 
from two coxal bones, two femurs, and two tibiae were 
harvested and separately transplanted into six secondary 
recipients (mice 1–6). Secondary transplantations were 
performed 4 mo after the primary transplantation.  
(B) Representative flow cytometry plots show human 
hematopoietic repopulation in the peripheral blood of 
the six secondary recipients 3 mo later. Two independent 
experiments were performed. mCD45, mouse CD45.2424 Highly potent human HSCs | Ivanovs et al.
Using stochastic analyses, it has been shown that adult 
human HSCs replicate every 40 wk (Catlin et al., 2011). Our 
findings indicate that the extensive expansion of HSCs from 
the early human embryo occurs through replication every 
3.5–4 wk or even more frequently, considering that HSCs 
also produce mature blood cells. This enormous regenerative 
capacity of early HSCs is consistent with them being found­
ers of the adult hematopoietic system in the human.
We have shown that within the human AGM region 
HSCs emerge in the dorsal aorta. According to current views, 
it is possible that HSCs emerge in intraaortic cell clusters 
budding from the floor of the dorsal aorta (Jaffredo et al., 
1998; Taoudi et al., 2008; Yokomizo and Dzierzak, 2010). In 
human, formation of such CD34+CD45+ cell clusters occurs 
between CS 12 and 16 (Tavian et al., 1996, 1999). Using 
limiting dilution analysis, we have shown that one human 
AGM region contains between one and three HSCs; how­
ever, the number of intraaortic cell clusters is much higher 
(Tavian et al., 1996, 1999), suggesting that not every cluster 
contains HSCs. Furthermore, although HSCs are still de­
tected at CS 17, intraaortic cell clusters are reported to 
disappear by that stage (Tavian et al., 1996, 1999), indicat­
ing that the link between HSCs and hematopoietic cell 
clusters needs to be elucidated further. Notably, the matu­
ration of definitive HSCs in the mouse embryo also occurs 
underneath the luminal layer of the dorsal aorta (Rybtsov 
et al., 2011).
As expected, HSC activity in the AGM region precedes 
that in the liver, which emerges there only after CS 17. Our 
data highlight the importance of in vivo long­term repopula­
tion assays, as previous immunohistological and in vitro stud­
ies have suggested that HSCs appear in the human embryonic 
liver around CS 13 (Tavian et al., 1999). Recent transplanta­
tion experiments have shown that HSCs colonize the human 
embryonic liver around week 7–8 of development, which 
follows the stages we studied (Oberlin et al., 2010).
We demonstrate that in the human, in contrast to the 
mouse (Gekas et al., 2005; Ottersbach and Dzierzak, 2005), 
placenta acquires HSC activity long after the emergence of 
HSCs in the AGM region, indicating that in the human, 
placenta might be a secondary site for HSCs. Our data vary 
from a recent study’s observation that the human placenta 
harbors HSCs from week 6 of development (as postmen­
strual gestational age was employed, it is comparable with CS 12 
or 13; Robin et al., 2009). In that study, NOD.CB17­ 
Prkdcscid (NOD/SCID) recipient mice, which are less recep­
tive to human HSCs than NSG mice (McDermott et al., 
2010), were used. The authors used a highly sensitive PCR 
analysis to detect repopulation with 6–8­wk­old placenta, 
identifying one human cell in 100,000 mouse cells. In the 
absence of flow cytometry analysis, a persistence of small num­
bers of some placenta­derived nonhematopoietic cells in re­
cipients could not be excluded. However, the presence of 
multipotent HSCs in the placenta was convincingly shown 
by flow cytometry starting from week 9 of development 
(Robin et al., 2009).
resolved, possibly because of considerably longer develop­
ment of the human embryo.
Our data indicate that early embryonic HSCs possess a 
considerably  higher  self­renewal  capacity  compared  with 
UCB and adult BM HSCs (Guenechea et al., 2001; McKenzie 
et al., 2006; Liu et al., 2010). Upon transplantation into 
NSG mice, a single HSC from the human AGM region pro­
duces at least 300 daughter HSCs during a period of 8 mo; 
this unprecedented self­renewal capacity has not been previ­
ously described for human or for mouse AGM region–derived 
HSCs. It is likely because of this that the percentage of 
human leukocytes in the recipients’ peripheral blood pro­
gressively increased, reaching up to 90% of total blood leuko­
cytes. To achieve the same effect with UCB or adult BM, 
considerably higher numbers of HSCs need to be trans­
planted (Liu et al., 2010). More recent data suggest that 
40% blood chimerism can be achieved 8 mo after trans­
plantation of 10–20 UCB HSCs per one NSG mouse (Notta 
et al., 2011).
Figure 6.  Daughter human AGM region-derived HSCs in primary 
recipients are CD34+CD38/lo. (A) 7 mo after primary transplantation, 
BM of NSG mice repopulated with CS 16 and 17 AGM regions was sorted 
into four cell populations based on expression of human CD34 and CD38 
antigens (two independent experiments). (B) Cells of each sorted popula-
tion were injected into secondary recipients as indicated, and peripheral 
blood was analyzed 2 mo later. Two independent experiments were per-
formed. K, multiple of thousand; M, multiple of million.JEM Vol. 208, No. 12 
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flow cytometry analysis was performed to detect the presence of human   
hematopoietic cells. The peripheral blood, BM, spleen, and thymus of 
engrafted NSG mice were further analyzed by flow cytometry analysis. The 
BM and spleen from primary recipients were used in secondary transplanta­
tion experiments.
Recipient mouse tissues. To collect recipient mouse tissues, buffer 2 sup­
plemented with 2 mM of EDTA was used. NSG mice transplanted with 
human AGM region, yolk sac, liver, umbilical cord, placental cells, or BM 
from primary recipients were bled by tail vein nicking, and erythrocytes were 
lysed using Pharm Lyse Buffer (BD) according to the manufacturer’s instruc­
tions. To analyze hematopoietic tissues, the spleen, thymus, long bones, 
coxal bones, and sternum were obtained. Spleen and thymus were gently 
mashed in a small volume of the buffer through a 40­µm nylon cell strainer. 
The BM was flushed out from the bones, and a single­cell suspension was 
prepared by gentle pipetting. A cell fraction associated with endosteum was 
obtained from remaining bones after treatment with collagenase/dispase and 
DNase I at 37°C for 40 min and added to the flushed­out BM fraction. The 
cells were spun down, resuspended in buffer 2 and kept on ice until trans­
plantation. To calculate the proportion of total BM transplanted into sec­
ondary recipients, we used previously reported data on the distribution of 
BM cells in different mouse bones (Boggs, 1984).
Human CFU-C assay. Human CFU­Cs in the BM of NSG recipient mice 
were detected by plating in triplicates 10,000–25,000 BM nucleated cells in 
the  MethoCult  H4034  Optimum  Medium  (StemCell  Technologies) 
according to the manufacturer’s recommendations. The BM from a non­
transplanted NSG mouse was used as a negative control. Cells were incu­
bated at 37°C in 5% CO2 and ≥95% humidity for 14 d. Hematopoietic colonies 
were enumerated microscopically. Some individual colonies were subject to 
flow cytometry analysis after labeling hematopoietic cells with anti–human 
CD45 and CD235a and anti–mouse CD45 and Ter119 antibodies.
Antibodies, flow cytometry analysis, and FACS. The following mouse 
anti–human monoclonal antibodies (all from BD) were used for flow cytometry 
analysis and/or FACS: CD3­APC, PE, and PerCP (clones SK7 and SP34­2), 
CD4­APC and APC­Cy7 (clone RPA­T4), CD8­PE and PE­Cy7 (clone 
RPA­T8), CD11b­PE­Cy7 (clone ICRF44), CD13­APC (clone WM15), 
CD14­APC and APC­Cy7 (clones M5E2 and MP9), CD19­PE (clone 
HIB19), CD33­PE (clone WM53), CD34­APC (clone 8G12), CD38­PE 
(clone HIT2), CD41a­FITC (HIP8), CD45­Biotin, FITC, and V450 (clone 
HI30), CD66b­FITC (clone G10F5), CD94­APC (clone HP­3D9), CD235a­
APC (clone GA­R2), IgM­Biotin (clone G20­127),  TCR­FITC (clone 
WT31),  TCR­PE (clone 11F2). Appropriate isotype controls, streptavi­
din­APC, rat anti–mouse CD45­APC (clone 30­F11), and Ter119­PE and 
FITC were also purchased from BD. The Human FcR Blocking Reagent 
(Miltenyi Biotec) and anti–mouse CD16/32 purified monoclonal antibody 
(clone 93; eBioscience) were used to prevent unwanted binding of antibodies to 
Fc receptors. All of the aforementioned antibodies and reagents were used at 
final concentrations recommended by manufacturers or determined by in­
house titration. Cell labeling and washes were performed in Ca2+ and Mg2+­free 
PBS supplemented with 2% heat­inactivated FBS. For dead cell exclu­
sion the buffer was supplemented with 1.5 µg/ml of 7­amino­actinomycin 
(eBioscience). A FACSCalibur (BD), LSRFortessa (BD), or CyAn ADP 
(Dako) instruments were used for flow cytometry analysis. FACS and postsort 
purity check were performed on a FACSAria II instrument (BD). Sorted cells 
were spun down, resuspended in buffer 2, and kept on ice until transplantation. 
Flow cytometry data were analyzed with FlowJo v7.6.1 software (Tree Star).
STR analysis. Genomic DNA was extracted from peripheral blood, spleen, 
and/or BM cells obtained from NSG mice repopulated with human hemato­
poietic cells and from embryonic or fetal donor tissues. For this, the QIAamp 
DNA Investigator Kit (QIAGEN) and a QIAcube robotic instrument 
(QIAGEN) were used. DNA quantification was performed with the Plexor 
HY System (Promega) and an Mx3500P real­time PCR machine (Stratagene). 
In summary, we provide a systematic spatiotemporal pic­
ture of HSC emergence in the early human embryo and iden­
tify the AGM region as the primary source of HSCs with 
unprecedented self­renewal capacity. Future comparative stud­
ies of early human embryonic HSCs and their fetal, neonatal, 
and adult counterparts may shed light on the mechanisms of 
HSC self­renewal and aging.
MATERIALS AND METHODS
Human embryonic and fetal tissues. Human embryonic and fetal tissues 
were obtained immediately after elective termination of pregnancy. The 
procedure was performed using mifepristone and misoprostol. The study was 
approved by the Lothian Research Ethics Committee. Each patient gave in­
formed consent in writing. The developmental stage of human embryos was 
determined according to the Carnegie staging system (O’Rahilly and Müller, 
1987). The postmenstrual gestational age of human fetuses was determined 
using medical ultrasonography. Tissue dissection was performed in buffer 1 
(PBS with Ca2+ and Mg2+ [Sigma­Aldrich] supplemented with 7% heat­
inactivated FBS [PAA Laboratories], 100 IU/ml of penicillin [Invitrogen], 
and 100 µg/ml of streptomycin [Invitrogen]). The dissection procedure was 
similar to that previously described for the mouse embryo (Medvinsky et al., 
2008). For the enzymatic treatment of the human AGM region, yolk sac, 
liver, and umbilical cord, 1 mg/ml of collagenase/dispase (Roche), and 
0.12 mg/ml of DNase I (Roche) were added to buffer 1 and incubated at 
37°C for 40 min. For the enzymatic treatment of placental tissue, two previ­
ously published protocols were employed (Bárcena et al., 2009; Robin et al., 
2009). In the majority of experiments with the human placenta, we omitted 
the Ficoll­Paque density gradient separation step to minimize cell losses. By the 
end of enzymatic treatment, tissue digests were washed with buffer 2 which, 
compared with buffer 1, was made with Ca2+ and Mg2+­free PBS. For prep­
aration of placental cells, in contrast to other tissues, 2 mM of EDTA was 
added to this buffer. After the first wash with buffer 2, tissue digests were 
pipetted gently to prepare a single­cell suspension. Human AGM region, 
yolk sac, liver, and umbilical cord cells were washed an additional time with 
buffer 2. Placental cells were passed through a 40­µm nylon cell strainer (BD) 
and washed four more times. Finally, cells were resuspended in buffer 2 and 
kept on ice until transplantation. Throughout the manuscript “independent” 
refers to those experiments performed with different human embryos.
Long-term repopulation assays. NSG mice were used as recipients for 
human HSCs. Animals were housed and bred within the University of 
Edinburgh, Edinburgh, Scotland, UK. Experiments with animals were 
approved by the Animal Welfare Committee of the University of Edinburgh 
and were performed according to the provisions of the Animal (Scientific 
Procedures) Act 1986 under the project license granted by the Home Office. 
All researchers who performed experiments with the mice held personal 
licenses granted by the Home Office. Mice were kept under specific 
pathogen–free  conditions.  Acidified  (pH  3.0)  autoclaved  water  supple­
mented with 1.67 mg/ml of neomycin (Invitrogen) and ­irradiated chow 
diet was provided ad libitum. Animals were exposed to 14­h light and 10­h 
dark cycle. Up to 6 h before transplantation with human cells, 6–8­wk­old 
female NSG mice received a sublethal total body irradiation dose of 3.5 Gy 
at a rate of 0.75 Gy/min from a 137Cs source (GSR D1 ­irradiator; Gamma­
Service Medical). Animals were transplanted with cells intravenously via the 
tail vein. The number of transplanted embryonic cells was expressed in embryo 
equivalents (e.e.), defined as a unit of cells equivalent to the number present 
in one tissue. Starting from 6–8 wk after transplantation, NSG mice were 
bled by tail vein nicking every 1–2 mo, and human HSC contribution was 
assessed by flow cytometry analysis after labeling cells with anti–human CD45 
antibody. At the end of each experiment (usually 4–8 mo after transplanta­
tion), all recipients (including those found nonengrafted after peripheral 
blood analysis) were killed by dislocation of the neck according to the 
Schedule 1 of the Animal (Scientific Procedures) Act 1986, and their BM 
was collected. BM cells were labeled with anti–human CD45 antibody, and 2426 Highly potent human HSCs | Ivanovs et al.
Catlin, S.N., L. Busque, R.E. Gale, P. Guttorp, and J.L. Abkowitz. 2011. 
The replication rate of human hematopoietic stem cells in vivo. Blood. 
117:4460–4466. http://dx.doi.org/10.1182/blood­2010­08­303537
Conneally, E., J. Cashman, A. Petzer, and C. Eaves. 1997. Expansion in 
vitro of transplantable human cord blood stem cells demonstrated using 
a quantitative assay of their lympho­myeloid repopulating activity in 
nonobese diabetic­scid/scid mice. Proc. Natl. Acad. Sci. USA. 94:9836–
9841. http://dx.doi.org/10.1073/pnas.94.18.9836
Cotton, E.A., R.F. Allsop, J.L. Guest, R.R. Frazier, P. Koumi, I.P. Callow, 
A. Seager, and R.L. Sparkes. 2000. Validation of the AMPFlSTR SGM 
plus system for use in forensic casework. Forensic Sci. Int. 112:151–161. 
http://dx.doi.org/10.1016/S0379­0738(00)00182­1
Cumano, A., J.C. Ferraz, M. Klaine, J.P. Di Santo, and I. Godin. 2001. 
Intraembryonic, but not yolk sac hematopoietic precursors, isolated be­
fore circulation, provide long­term multilineage reconstitution. Immunity. 
15:477–485. http://dx.doi.org/10.1016/S1074­7613(01)00190­X
de  Bruijn,  M.F.,  N.A.  Speck,  M.C.  Peeters,  and  E.  Dzierzak.  2000. 
Definitive hematopoietic stem cells first develop within the major arterial 
regions of the mouse embryo. EMBO J. 19:2465–2474. http://dx.doi 
.org/10.1093/emboj/19.11.2465
de Bruijn, M.F., X. Ma, C. Robin, K. Ottersbach, M.J. Sanchez, and E. 
Dzierzak. 2002. Hematopoietic stem cells localize to the endothelial cell 
layer in the midgestation mouse aorta. Immunity. 16:673–683. http://
dx.doi.org/10.1016/S1074­7613(02)00313­8
Dieterlen­Lievre, F. 1975. On the origin of haemopoietic stem cells in the 
avian embryo: an experimental approach. J. Embryol. Exp. Morphol. 33: 
607–619.
Dykstra, B., D. Kent, M. Bowie, L. McCaffrey, M. Hamilton, K. Lyons, 
S.J. Lee, R. Brinkman, and C. Eaves. 2007. Long­term propagation of 
distinct hematopoietic differentiation programs in vivo. Cell Stem Cell. 
1:218–229. http://dx.doi.org/10.1016/j.stem.2007.05.015
Dzierzak, E., and N.A. Speck. 2008. Of lineage and legacy: the development 
of  mammalian  hematopoietic  stem  cells.  Nat.  Immunol.  9:129–136. 
http://dx.doi.org/10.1038/ni1560
Gekas, C., F. Dieterlen­Lièvre, S.H. Orkin, and H.K. Mikkola. 2005. The 
placenta is a niche for hematopoietic stem cells. Dev. Cell. 8:365–375. 
http://dx.doi.org/10.1016/j.devcel.2004.12.016
Guenechea, G., O.I. Gan, C. Dorrell, and J.E. Dick. 2001. Distinct classes 
of human stem cells that differ in proliferative and self­renewal potential. 
Nat. Immunol. 2:75–82. http://dx.doi.org/10.1038/83199
Hu, Y., and G.K. Smyth. 2009. ELDA: extreme limiting dilution analysis 
for comparing depleted and enriched populations in stem cell and other 
assays. J. Immunol. Methods. 347:70–78. http://dx.doi.org/10.1016/ 
j.jim.2009.06.008
Ishikawa,  F.,  M.  Yasukawa,  B.  Lyons,  S.  Yoshida,  T.  Miyamoto,  G. 
Yoshimoto,  T.  Watanabe,  K.  Akashi,  L.D.  Shultz,  and  M.  Harada. 
2005. Development of functional human blood and immune systems 
in NOD/SCID/IL2 receptor  chain(null) mice. Blood. 106:1565–1573. 
http://dx.doi.org/10.1182/blood­2005­02­0516
Jaffredo,  T.,  R.  Gautier,  A.  Eichmann,  and  F.  Dieterlen­Lièvre.  1998. 
Intraaortic hemopoietic cells are derived from endothelial cells during 
ontogeny. Development. 125:4575–4583.
Kaufman, D.S. 2009. Toward clinical therapies using hematopoietic cells de­
rived from human pluripotent stem cells. Blood. 114:3513–3523. http://
dx.doi.org/10.1182/blood­2009­03­191304
Kissa, K., and P. Herbomel. 2010. Blood stem cells emerge from aortic 
endothelium by a novel type of cell transition. Nature. 464:112–115. 
http://dx.doi.org/10.1038/nature08761
Kumaravelu, P., L. Hook, A.M. Morrison, J. Ure, S. Zhao, S. Zuyev, J. 
Ansell, and A. Medvinsky. 2002. Quantitative developmental anatomy 
of definitive haematopoietic stem cells/long­term repopulating units 
(HSC/RUs): role of the aorta­gonad­mesonephros (AGM) region and 
the yolk sac in colonisation of the mouse embryonic liver. Development. 
129:4891–4899.
Larochelle, A., J. Vormoor, H. Hanenberg, J.C. Wang, M. Bhatia, T. Lapidot, 
T. Moritz, B. Murdoch, X.L. Xiao, I. Kato, et al. 1996. Identification 
of primitive human hematopoietic cells capable of repopulating NOD/
SCID mouse bone marrow: implications for gene therapy. Nat. Med. 
2:1329–1337. http://dx.doi.org/10.1038/nm1296­1329
DNA quantification values were determined using the Plexor Data Analysis 
Software (Promega). DNA samples and PCR positive and negative controls 
were amplified with the AmpFlSTR SGM Plus PCR Amplification Kit 
(Applied Biosystems). PCR products were detected on a 3130 Genetic Analyzer 
(Applied Biosystems). Handling of raw data and genotyping were performed 
with GeneMapper ID v3.2.1 software (Applied Biosystems). All the reagents 
and instruments listed above were used according to manufacturers’ recom­
mendations. DNA match probabilities were calculated based on allele fre­
quencies in Scottish Caucasian population.
Limiting dilution analysis. Limiting dilution analysis was performed using 
ELDA software (Hu and Smyth, 2009) available at http://bioinf.wehi.edu 
.au/software/elda/.
Online supplemental material. Tables S1–S6 show STR analysis data 
confirming either embryonic or maternal origin of hematopoietic re­
population in recipients transplanted with human embryo or placenta­
derived cells. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20111688/DC1.
We thank the patients for donating tissues; research nurses A. Saunderson,  
J. Creiger, and I. Morton for patient recruitment; J. Verth, R. McInnes, C. Watt,  
C. Manson, and their staff for animal maintenance; S. Monard for cell sorting; 
P. Travers and K. Samuel for valuable advice; and S. Gordon-Keylock for useful 
comments on the manuscript.
Financial support for this study was provided by grants from the Leukaemia 
and Lymphoma Research (to A. Medvinsky), Medical Research Council  
(to A. Medvinsky and R.A. Anderson), Biotechnology and Biological Sciences 
Research Council (to A. Medvisnky), and Wellcome Trust (to A. Medvinsky).  
The Medical Research Council awarded A. Ivanovs with a PhD studentship.
Author contributions: A. Ivanovs performed the majority of transplantation 
experiments, interpreted experimental data, and wrote the manuscript; S. Rybtsov 
performed some transplantation experiments and interpreted experimental data; 
L. Welch performed STR analysis and interpreted its data; R.A. Anderson and 
M.L. Turner interpreted experimental data; and A. Medvisnky directed the study, 
interpreted experimental data, and wrote the manuscript.
The authors declare no competing financial interests.
Submitted: 11 August 2011
Accepted: 14 October 2011
REFERENCES
Bárcena, A., M. Kapidzic, M.O. Muench, M. Gormley, M.A. Scott, J.F. 
Weier, C. Ferlatte, and S.J. Fisher. 2009. The human placenta is a hema­
topoietic organ during the embryonic and fetal periods of development. 
Dev. Biol. 327:24–33. http://dx.doi.org/10.1016/j.ydbio.2008.11.017
Bertrand, J.Y., N.C. Chi, B. Santoso, S. Teng, D.Y. Stainier, and D. Traver. 
2010. Haematopoietic stem cells derive directly from aortic endothe­
lium during development. Nature. 464:108–111. http://dx.doi.org/ 
10.1038/nature08738
Bhatia, M., J.C. Wang, U. Kapp, D. Bonnet, and J.E. Dick. 1997. Purification 
of primitive human hematopoietic cells capable of repopulating immune­
deficient mice. Proc. Natl. Acad. Sci. USA. 94:5320–5325. http://dx.doi 
.org/10.1073/pnas.94.10.5320
Boggs, D.R. 1984. The total marrow mass of the mouse: a simplified 
method of measurement. Am. J. Hematol. 16:277–286. http://dx.doi 
.org/10.1002/ajh.2830160309
Boisset, J.C., W. van Cappellen, C. Andrieu­Soler, N. Galjart, E. Dzierzak, 
and C. Robin. 2010. In vivo imaging of haematopoietic cells emerg­
ing from the mouse aortic endothelium. Nature. 464:116–120. http://
dx.doi.org/10.1038/nature08764
Cashman,  J.D.,  T.  Lapidot,  J.C.  Wang,  M.  Doedens,  L.D.  Shultz,  P. 
Lansdorp, J.E. Dick, and C.J. Eaves. 1997. Kinetic evidence of the re­
generation of multilineage hematopoiesis from primitive cells in normal 
human bone marrow transplanted into immunodeficient mice. Blood. 
89:4307–4316.JEM Vol. 208, No. 12 
Article
2427
Robin, C., K. Bollerot, S. Mendes, E. Haak, M. Crisan, F. Cerisoli, I. Lauw, 
P. Kaimakis, R. Jorna, M. Vermeulen, et al. 2009. Human placenta 
is  a  potent  hematopoietic  niche  containing  hematopoietic  stem  and 
progenitor cells throughout development. Cell Stem Cell. 5:385–395. 
http://dx.doi.org/10.1016/j.stem.2009.08.020
Rybtsov,  S.,  M.  Sobiesiak,  S.  Taoudi,  C.  Souilhol,  J.  Senserrich,  A. 
Liakhovitskaia, A. Ivanovs, J. Frampton, S. Zhao, and A. Medvinsky. 
2011.  Hierarchical  organization  and  early  hematopoietic  specifica­
tion of the developing HSC lineage in the AGM region. J. Exp. Med. 
208:1305–1315. http://dx.doi.org/10.1084/jem.20102419
Shultz, L.D., B.L. Lyons, L.M. Burzenski, B. Gott, X. Chen, S. Chaleff, M. 
Kotb, S.D. Gillies, M. King, J. Mangada, et al. 2005. Human lymphoid 
and myeloid cell development in NOD/LtSz­scid IL2R   null mice 
engrafted with mobilized human hemopoietic stem cells. J. Immunol. 
174:6477–6489.
Szilvassy, S.J., R.K. Humphries, P.M. Lansdorp, A.C. Eaves, and C.J. Eaves. 
1990.  Quantitative  assay  for  totipotent  reconstituting  hematopoietic 
stem cells by a competitive repopulation strategy. Proc. Natl. Acad. Sci. 
USA. 87:8736–8740. http://dx.doi.org/10.1073/pnas.87.22.8736
Taoudi, S., and A. Medvinsky. 2007. Functional identification of the he­
matopoietic stem cell niche in the ventral domain of the embryonic 
dorsal aorta. Proc. Natl. Acad. Sci. USA. 104:9399–9403. http://dx.doi 
.org/10.1073/pnas.0700984104
Taoudi, S., C. Gonneau, K. Moore, J.M. Sheridan, C.C. Blackburn, E. 
Taylor, and A. Medvinsky. 2008. Extensive hematopoietic stem cell 
generation in the AGM region via maturation of VE­cadherin+CD45+ 
pre­definitive  HSCs.  Cell  Stem  Cell.  3:99–108.  http://dx.doi.org/ 
10.1016/j.stem.2008.06.004
Tavian, M., L. Coulombel, D. Luton, H.S. Clemente, F. Dieterlen­Lièvre, 
and B. Péault. 1996. Aorta­associated CD34+ hematopoietic cells in the 
early human embryo. Blood. 87:67–72.
Tavian, M., M.F. Hallais, and B. Péault. 1999. Emergence of intraembryonic 
hematopoietic precursors in the pre­liver human embryo. Development. 
126:793–803.
Tavian, M., C. Robin, L. Coulombel, and B. Péault. 2001. The human embryo, 
but not its yolk sac, generates lympho­myeloid stem cells: mapping mul­
tipotent hematopoietic cell fate in intraembryonic mesoderm. Immunity. 
15:487–495. http://dx.doi.org/10.1016/S1074­7613(01)00193­5
van Rijn, R.S., E.R. Simonetti, A. Hagenbeek, M.C. Hogenes, R.A. de 
Weger, M.R. Canninga­van Dijk, K. Weijer, H. Spits, G. Storm, L. van 
Bloois, et al. 2003. A new xenograft model for graft­versus­host disease 
by intravenous transfer of human peripheral blood mononuclear cells 
in  RAG2­/­  gammac­/­  double­mutant  mice.  Blood.  102:2522–2531. 
http://dx.doi.org/10.1182/blood­2002­10­3241
Wang, J.C., M. Doedens, and J.E. Dick. 1997. Primitive human hematopoi­
etic cells are enriched in cord blood compared with adult bone marrow 
or mobilized peripheral blood as measured by the quantitative in vivo 
SCID­repopulating cell assay. Blood. 89:3919–3924.
Yokomizo, T., and E. Dzierzak. 2010. Three­dimensional cartography 
of hematopoietic clusters in the vasculature of whole mouse em­
bryos.  Development.  137:3651–3661.  http://dx.doi.org/10.1242/ 
dev.051094
Zovein, A.C., J.J. Hofmann, M. Lynch, W.J. French, K.A. Turlo, Y. Yang, 
M.S. Becker, L. Zanetta, E. Dejana, J.C. Gasson, et al. 2008. Fate trac­
ing reveals the endothelial origin of hematopoietic stem cells. Cell Stem 
Cell. 3:625–636. http://dx.doi.org/10.1016/j.stem.2008.09.018
Liu, C., B.J. Chen, D. Deoliveira, G.D. Sempowski, N.J. Chao, and R.W. 
Storms. 2010. Progenitor cell dose determines the pace and completeness 
of engraftment in a xenograft model for cord blood transplantation. Blood. 
116:5518–5527. http://dx.doi.org/10.1182/blood­2009­12­260810
Manz, M.G. 2007. Human­hemato­lymphoid­system mice: opportunities 
and challenges. Immunity. 26:537–541. http://dx.doi.org/10.1016/ 
j.immuni.2007.05.001
McDermott, S.P., K. Eppert, E.R. Lechman, M. Doedens, and J.E. Dick. 
2010. Comparison of human cord blood engraftment between immuno­
compromised mouse strains. Blood. 116:193–200. http://dx.doi.org/ 
10.1182/blood­2010­02­271841
McKenzie, J.L., O.I. Gan, M. Doedens, J.C. Wang, and J.E. Dick. 2006. 
Individual stem cells with highly variable proliferation and self­renewal 
properties comprise the human hematopoietic stem cell compartment. 
Nat. Immunol. 7:1225–1233. http://dx.doi.org/10.1038/ni1393
Medvinsky, A., and E. Dzierzak. 1996. Definitive hematopoiesis is auto­
nomously initiated by the AGM region. Cell. 86:897–906. http://dx.doi 
.org/10.1016/S0092­8674(00)80165­8
Medvinsky, A.L., N.L. Samoylina, A.M. Müller, and E.A. Dzierzak. 1993. 
An early pre­liver intraembryonic source of CFU­S in the developing 
mouse. Nature. 364:64–67. http://dx.doi.org/10.1038/364064a0
Medvinsky, A., S. Taoudi, S. Mendes, and E. Dzierzak. 2008. Analysis and 
manipulation of hematopoietic progenitor and stem cells from murine 
embryonic tissues. Curr. Protoc. Stem Cell Biol. Chapter 2:2A: 6.
Medvinsky, A., S. Rybtsov, and S. Taoudi. 2011. Embryonic origin of 
the adult hematopoietic system: advances and questions. Development. 
138:1017–1031. http://dx.doi.org/10.1242/dev.040998
Moore, M.A., and D. Metcalf. 1970. Ontogeny of the haemopoietic sys­
tem: yolk sac origin of in vivo and in vitro colony forming cells in the 
developing mouse embryo. Br. J. Haematol. 18:279–296. http://dx.doi 
.org/10.1111/j.1365­2141.1970.tb01443.x
Müller, A.M., A. Medvinsky, J. Strouboulis, F. Grosveld, and E. Dzierzak. 
1994. Development of hematopoietic stem cell activity in the mouse 
embryo.  Immunity.  1:291–301.  http://dx.doi.org/10.1016/1074­ 
7613(94)90081­7
Notta, F., S. Doulatov, E. Laurenti, A. Poeppl, I. Jurisica, and J.E. Dick. 
2011. Isolation of single human hematopoietic stem cells capable of 
long­term  multilineage  engraftment.  Science.  333:218–221.  http://
dx.doi.org/10.1126/science.1201219
O’Rahilly, R., and F. Müller. 1987. Developmental stages in human em­
bryos. Carnegie Institution of Washington, Washington. 306 pp.
Oberlin, E., M. Tavian, I. Blazsek, and B. Péault. 2002. Blood­forming 
potential of vascular endothelium in the human embryo. Development. 
129:4147–4157.
Oberlin,  E.,  M.  Fleury,  D.  Clay,  L.  Petit­Cocault,  J.J.  Candelier,  B. 
Mennesson, T. Jaffredo, and M. Souyri. 2010. VE­cadherin expression 
allows identification of a new class of hematopoietic stem cells within 
human  embryonic  liver.  Blood.  116:4444–4455.  http://dx.doi.org/ 
10.1182/blood­2010­03­272625
Osawa, M., K. Hanada, H. Hamada, and H. Nakauchi. 1996. Long­term l 
ymphohematopoietic  reconstitution  by  a  single  CD34­low/negative   
hematopoietic stem cell. Science. 273:242–245. http://dx.doi.org/ 
10.1126/science.273.5272.242
Ottersbach, K., and E. Dzierzak. 2005. The murine placenta contains he­
matopoietic stem cells within the vascular labyrinth region. Dev. Cell. 
8:377–387. http://dx.doi.org/10.1016/j.devcel.2005.02.001